|Day Low/High||0.00 / 0.00|
|52 Wk Low/High||0.00 / 0.00|
Elan Corporation, plc (NYSE:ELN) announced today that its Board of Directors has approved the spin-off of the discovery science and Neotope Biosciences from the company.
Sirius XM Radio and Walt Disney are among companies scheduled to post quarterly results on Tuesday.
Stocks have roared back in the past few weeks with defensive sectors leading the way but that's not the whole story.
Elan Corporation, plc (NYSE:ELN) announced today that Johnson & Johnson has issued a press release regarding the discontinuation of Phase 3 development of bapineuzumab IV in mild to moderate Alzheimer’s.
Elan Management Discusses Q2 2012 Results - Earnings Call Transcript
Elan Corporation, plc today reported its second quarter and first half 2012 financial results.
Shares are down now but they could be worth buying later in the week.
Elan Corporation, plc (NYSE:ELN) announced today that Pfizer has issued a top-line result in the first of four Bapineuzumab Phase 3 studies carried out by Pfizer and Janssen AI.
The first of four phase III trials of bapineuzumab is a failure, Pfizer says.
Elan Corporation, plc (NYSE: ELN) announced today that it will host a conference call on Wednesday, July 25, 2012 at 8:30 a.
University College Dublin (UCD) and Elan Corporation plc, (NYSE: ELN) today announced two scholarships and an annual lecture series at University College Dublin (UCD) in the 'Business of Biotechnology' named in honour ...
An undervalued stock could move higher if Alkermes continues to grow through acquisitions.
Elan Corporation, plc (NYSE: ELN) announced today that it will present at the Jefferies 2012 Global Healthcare Conference on Monday, June 4th at 9:30am Eastern Daylight Time (EDT), 2:30pm British Summer Time (BST).
TheStreet's Adam Feuerstein has compiled a list of drugs with crucial, stock-moving clinical trial catalysts for the remainder of 2012.
Biogen Idec (NASDAQ: BIIB) and Elan Corporation, plc (NYSE: ELN) today announced that the New England Journal of Medicine published research from the companies’ global risk management program that...
Health care investor Nate Sadeghi says Pfizer is holding back bad news on its Alzheimer's drug, tells Human Genome to sell to Glaxo and likes Vertex and Gilead Sciences.
Elan Corporation, plc, today reported its first quarter 2012 financial results.
Elan Corporation, plc (NYSE: ELN) announced today that it will host a conference call on Thursday, April 26, 2012 at 8:30 a.
TheStreet's biotech contributor Nathan Sadeghi-Nejad looks back at his hits and misses with Amylin, Elan, Gilead Sciences, Onyx and Verastem.
Remembering the failed back story of Elan's Alzheimer's drug bapineuzumab as phase III trial results loom.
These stocks look poised to break out and trade higher from current levels.
Elan Corporation, plc (NYSE: ELN) today raised approximately $381 million in net proceeds from the sale of 76% (24.
The Chairman of Elan (NYSE:ELN), Mr. Robert Ingram today provided an update on CEO succession: “On June 3, 2010, Elan communicated that, as part of its prudent executive succession management process,...
The amyloid beta hypothesis doesn't explain Alzheimer's, which leaves Elan and its partners in trouble.
Elan Corporation, plc today reported its fourth quarter and full-year 2011 financial results.
Elan Corporation, plc (NYSE:ELN) announced today that it will present at the Leerink Swann 2012 Global Healthcare Conference on Wednesday February 15, 2012 at 2.
Biogen Idec (NASDAQ: BIIB) and Elan Corporation, plc (NYSE: ELN) today announced a global Phase 3b study, ASCEND, that is being conducted to evaluate the effectiveness of TYSABRI as a treatment for...
Today Biogen Idec (NASDAQ: BIIB) and Elan Corporation, plc (NYSE: ELN) announced that the U.
Medivation puts the Alzheimer's drug Dimebon on the shelf and will now focus solely on its promising prostate cancer drug.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.